Spots Global Cancer Trial Database for Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses

Official Title: UCI 14-92 / HS#2015-1889: Phase IV Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses

Study ID: NCT03327831

Conditions

Actinic Keratosis

Interventions

Aminolevulinic Acid

Study Description

Brief Summary: Photodynamic therapy is an effective treatment for actinic keratoses. In the United States topical aminolevulinic acid (ALA) is approved as a photosensitizing agent for this treatment, and it has traditionally been activated with the use of an in-office artificial light source. This clinical trial seeks to measure the safety and efficacy of using natural sunlight to activate the ALA.

Detailed Description: * Initial Visit: * study inclusion criteria reviewed * consent forms reviewed * creation of facial map for actinic keratoses * face cleansed with chlorhexidine soap * light curettage of precancerous skin lesions * application of topical aminolevulinic acid (ALA) * application of sunscreen * patient then spends 2 hours outdoors in a shaded area * after treatment the patient is to remain indoors for 48 hours * 3 month follow up visit - facial map of actinic keratoses used to document treatment response * 6 month follow up visit * facial map of actinic keratoses used to document treatment response